Sandoz Q1 Strong Start To The Year With Biosimilars Growth

Sandoz Q1 Strong Start To The Year With Biosimilars Growth

Tue, May 7th 2024

Sandoz, a Novartis spin-off, kicks off the year with a 5% revenue increase, driven by significant growth in its biosimilars division.

KEYSTONE/Georgios Kefalas

The former generics subsidiary of the pharmaceutical group Novartis has grown faster with its lucrative biosimilars than with “normal” generics.

Revenue between January and March climbed by 5% to 2.5 billion US dollars, as the Group announced on Tuesday. At constant exchange rates, the increase would have been 6%.

The generics business contributed 1.9 billion dollars to total sales and thus remained stable compared to the same period of the previous year.

Sandoz attributes this to factors including an exceptional cough and cold season in the first half of 2023 and the timing of new product launches in the US, which would have offset the solid volume growth.

In contrast, the smaller biosimilar division grew by 21% to 0.6 billion. This significantly stronger growth was due, among other things, to the ongoing market launch of the highly concentrated formulation of the biosimilar Hyrimoz (anti-inflammatory) and the acquisition of Cimerli.

The Basel-based company confirmed its previous target for the further course of business: net sales are expected to grow in the mid-single-digit range. The core EBITDA margin is expected to be around 20% in 2024. The future dividend payout is expected to be between 30 and 40 percent.

©Keystone/SDA

Related Stories

Credit Suisse CEO To Step Down As UBS Merger Accelerates
Thumbnail

UBS plans to dissolve Credit Suisse's management in the coming weeks, with CEO Ulrich Körner leaving post-merger,...

Swiss Retail Sector Sees Mixed Performance in Q1 2024
Thumbnail

The Swiss retail sector reported a 1.7% increase in sales in Q1 2024, with food sales up 4.2% and non-food sales down...

Swiss Media Empire TX Group Layoffs Staff
Thumbnail

TX Group, a major Swiss media conglomerate, unexpectedly lays off staff, sparking criticism as it seeks government...

Sandoz Q1 Strong Start To The Year With Biosimilars Growth
Thumbnail

Sandoz sees a solid financial start in 2024, with biosimilars growing 21%, contributing to a total revenue of $2.5...

Swiss Politician Charged With Faking Covid Certificates
Thumbnail

Christophe Loperetti sentenced to 15 months' probation for orchestrating a counterfeit Covid certificate trade....

Switzerland To Pay The EU: ‘Cohesion Fund’
Thumbnail

Switzerland enhances cooperation with the EU, committing to regular cohesion payments....

Hochdorf: Shareholders To Change The Board
Thumbnail

Hochdorf faces a significant board transformation as Newlat proposes six new candidates, predominantly Italian....

Stay in Touch

Noteworthy

the swiss times
A production of UltraSwiss AG, 6340 Baar, Switzerland
Copyright © 2024 UltraSwiss AG 2024 All rights reserved